Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Brief Version (N/A)
Non-Nucleoside Reverse Transcriptase Inhibitors
Overview
Five non-nucleoside analogue reverse transcriptase inhibitors (NNRTIs) are currently U.S. Food and Drug Administration (FDA) approved: delavirdine, efavirenz, etravirine, nevirapine, and rilpivirine. Delavirdine is no longer available in the United States.
Doravirine (Pifeltro, DOR)
Efavirenz (Sustiva, EFV)
Etravirine (Intelence, ETR)
Nevirapine (Viramune, NVP)
Rilpivirine (Edurant. RPV)
Glossary of Terms for Supplement |
---|
Carcinogenic = producing or tending to produce cancer
Genotoxic = damaging to genetic material such as DNA and chromosomes Mutagenic = inducing or capable of inducing genetic mutation Teratogenic = interfering with fetal development and resulting in birth defects |
Download Guidelines
- Full Guideline PDF ()
- Recommendations Only PDF (211 KB)
- Tables Only PDF (388 KB)
Related Content
- AIDSinfo Drug Database
- AIDSinfo Patient Materials: Preventing Mother-to-Child Transmission of HIV
- AIDSinfo Patient Materials: HIV Medicines During Pregnancy and Childbirth
- AIDSinfo Patient Materials: Protecting Baby from HIV
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Perinatal Guidelines Archive